ArticleIranian journal of medical sciences2026
The Impact of the COVID-19 Pandemic on Patients with Breast Cancer, Diagnostic Delays and Disease Progression: A Retrospective Study.
Article in Iranian journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most frequent malignancy among women. The COVID-19 pandemic significantly impacted healthcare systems, potentially affecting the management of this disease. Due to the critical importance of early diagnosis and treatment, and the limited data on the pandemic's specific effects, this study aimed to determine the correlation between the COVID-19 pandemic and various breast cancer parameters. Methods: This retrospective study included patients with breast cancer in Shiraz, Iran. Patients were divided into two groups, including those diagnosed before and after the start of the COVID-19 pandemic (from September 2018 to March 2021). Variables included demographic, clinical, and management features. Continuous variables were reported as mean±SD, and the categorical data were reported as frequency and percentage. The significance level was set as P<0.05. Results: The study documented 1,435 patients: 811 patients were diagnosed before the pandemic, and 624 patients were diagnosed after. The mean initial tumor size at the time of diagnosis was significantly larger in the post-pandemic group than the pre-pandemic group (2.29±1.44 vs. 2.11±1.39 cm, respectively; P=0.001). The distribution of cancer stages also differed significantly (P=0.001). While the prevalence of stage 1 disease was similar between groups (30.1% vs. 28.9%), the prevalence of stage 2 (14.8% vs. 8.5%) and stage 3 (10.1% vs. 7.0%) was significantly higher in the post-pandemic group (Stage 1: 30.1 vs. 28.9%, Stage 2: 8.5 vs. 14.8%, Stage 3: 7 vs. 10.1%; P=0.001). Conclusion: Following the COVID-19 pandemic, patients presented with significantly larger breast tumors, increased axillary involvement, and more advanced stages after the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.